Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Banxia Xiexin Decoction for Gut Microbiota Modulation
NCT07035613Completed
- Sponsor
- China Medical University Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Herbal Formulation
- Countries
- 1
01
Overview
Open-label, single-arm trial of Banxia Xiexin Decoction in inflammatory bowel disease (IBD), sponsored by China Medical University Hospital. Primary endpoint: Change in plasma IgA levels at Day 14. Started Feb 2024; status: completed.
02
Drugs
Banxia Xiexin Decoction
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07035613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035613.